Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

2008 Workforce Census Published - Royal Pharmaceutical Society Of Great Britain
The Royal Pharmaceutical Society of Great Britain has published its fourth Pharmacy
generic viagra online
Medtronic Clinical Trial Evaluating The Newest Radiofrequency Ablation Tools For Atrial Fibrillation Completes Enrollment
Medtronic, Inc. (NYSE:MDT) announced completion of enrollment in the TTOP-AF (Tailored Treatment of Permanent Atrial Fibrillation) clinical trial. The study is evaluating the use of the latest radiofrequency (RF) ablation technology, the Medtronic Ablation Frontiers Cardiac Ablation System, for the treatment of continuous atrial fibrillation (AF). A leading advancement from currently available RF ablation tools, the system is comprised of a RF generator (or energy ) and three anatomically shaped mapping and ablation catheters that target three areas of the heart for AF treatment. The system is approved for use in Europe and is under investigational use in the United States. Drugshop to buy zoloft online and other pills.
News of the day
Many In Congress Hold Stakes In Health Industry
"Almost 30 key lawmakers helping draft landmark health-care legislation have financial holdings in the industry, totaling nearly $11 million worth of personal investments in a sector that could be dramatically reshaped by this summer"s debate," The Washington Post reports. The list of members includes "Congress"s most powerful leaders and a bipartisan collection of lawmakers in key committee posts." For example, Senate Majority Leader Harry Reid, D-Nev., "has at least $50,000 invested in a health-care index" (fund), and Sen. Judd Gregg, R-NH, "a senior member of the health committee, has between $254,000 and $560,000 worth of stock holdings in major health-care companies, including Bristol-Myers Squibb and Merck." The data was part of a "release of financial disclosure forms for the House and Senate" on Friday.
Health Insurance

Atrium Medical Receives CE Mark For Its CinatraTM CoCr Coronary Stent System

Atrium Medical is pleased to announce that is has received CE Mark for a new generation Cobalt Chromium Coronary Stent System called Cinatra™. Cinatra™ is indicated for the treatment of coronary artery occlusive disease. Atrium is excited to release this best in class Cobalt Chromium Coronary Stent System that is extremely low in profile, ultra flexible, and highly deliverable. In an independent lab test, Atrium"s new Cinatra™ CoCr Stent was highlighted as having the lowest crossing profile and greatest flexibility when compared to the leading competitors.* The advanced design of the Cinatra™ CoCr Stent with its superior mechanical properties have produced excellent clinical results yielding a very low late lumen loss. Preliminary results from the CONFIRM 1 multi-center prospective trial have shown the Cinatra™ CoCr Stent to have a mean in-stent late lumen loss of 0.69 mm at 6 months. This low late lumen loss is clear evidence that Cinatra™ offers excellent clinical results and will offer cardiologists a new option when treating coronary artery disease. *Data on file at Atrium. Atrium


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009